Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer

Multiple randomized studies have shown that combination of chemotherapy and immune checkpoint inhibitors (ICIs) leads to better response rates and survival as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting a benefit to using ICIs in the neoadjuvant therapy of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tfayli, Arafat, Al Assaad, Majd, Fakhri, Ghina, Akel, Reem, Atwi, Hanine, Ghanem, Hady, El Karak, Fadi, Farhat, Fadi, Al Rabi, Kamal, Sfeir, Pierre, Youssef, Pierre, Mansour, Ziad, Assi, Hazem, Haidar, Mohamad, Abi Ghanem, Alain, Khalifeh, Ibrahim, Boulos, Fouad, Mahfouz, Ramy, Youssef, Bassem, Zeidan, Youssef, Bejjany, Rachelle, Khuri, Fadlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666740/
https://www.ncbi.nlm.nih.gov/pubmed/32991781
http://dx.doi.org/10.1002/cam4.3456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666740/
https://www.ncbi.nlm.nih.gov/pubmed/32991781
http://dx.doi.org/10.1002/cam4.3456

Ejemplares similares